Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Small Cell Lung Cancer | Faculty Presentation 2: Management of Relapsed/Refractory SCLC; Promising Investigational Agents and Strategies — Christine L Hann, MD, PhD

CME information and select publications

Featuring perspectives from Prof Thomas Powles, including the following topics:

• Circulating tumor DNA (ctDNA) analyses with adjuvant nivolumab for MIBC in the CheckMate 274 study (0:00)
• Use of ctDNA to guide response-adapted bladder preservation for patients with MIBC (2:27)
• ctDNA response-adapted treatment de-escalation for patients with metastatic urothelial carcinoma: The CT-READ trial (10:26)
• Emerging data and studies regarding urinary tumor DNA (18:04)

CME information and select publications

Featuring perspectives from Prof Ramez Eskander and Dr Bradley Monk, moderated by Dr Kathleen Moore, including the following topics:

• Introduction (0:00)
• Advances in Human Cadherin-6-Targeted Antibody-Drug Conjugates (ADCs) in Ovarian and Other Gynecologic Cancers — Dr Moore (1:30)
• Leveraging TROP2-Directed ADCs in Advanced Gynecologic Cancers — Prof Eskander (35:39)
• Tolerability and Other Practical Considerations with Novel Investigational ADCs in Advanced Gynecologic Cancers — Dr Monk (1:04:58)

CME information and select publications

• Current management of desmoid tumors: A review from the Desmoid Tumor Working Group (0:00)
• Long-term nirogacestat treatment in adult patients with desmoid tumors: Updated efficacy and safety from the Phase III DeFi trial (8:26)
• Phase IV trial of nirogacestat in adult premenopausal women with desmoid tumors (17:35)

Proceedings from a webinar on April 16, 2026, moderated by Dr Neil Love, including the following topics:

• Introduction: Research To Practice Paper of the Year! (0:00)
• Checkpoint Inhibitors for Localized Microsatellite Instability-High Tumors (11:12)
• Circulating Tumor DNA Assays (21:58)
• Checkpoint Inhibitors for Metastatic Disease (38:32)

CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Colorectal Cancer | Faculty Presentation 2: Optimizing the Care of Patients with Nonmetastatic Colorectal Cancer (CRC) — Arvind Dasari, MD, MS

CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Colorectal Cancer | Faculty Presentation 1: Recent Advances in the Management of Metastatic CRC (mCRC) — Anwaar Saeed, MD

CME information and select publications

Interview conducted on March 11, 2026, by Dr Neil Love, including the following topics:

• Circulating tumor DNA (ctDNA)-guided adjuvant therapy with atezolizumab for muscle-invasive bladder cancer (MIBC) (0:00)
• Use of ctDNA in guiding systemic treatment selection for patients with urothelial bladder cancer (10:03)
• ctDNA analyses with perioperative durvalumab for MIBC in the Phase III NIAGARA study (16:51)
• New research advances in the monitoring and management of urothelial bladder cancer (22:21)

CME information and select publications